CNS Drugs

, Volume 8, Issue 5, pp 402–408


Adis New Drug Profile

DOI: 10.2165/00023210-199708050-00006

Cite this article as:
Gunasekara, N.S. & Wiseman, L.R. CNS Drugs (1997) 8: 402. doi:10.2165/00023210-199708050-00006


▴ Naratriptan is a new serotonin 5-HT1B/1D receptor agonist that is indicated for the acute treatment of migraine.

In vitro and in vivo studies indicate that naratriptan mediates vasoconstriction in the cerebral vasculature and inhibits responses mediated by the trigeminal nerve.

▴ Studies in healthy volunteers demonstrate that naratriptan has good oral bioavailability.

▴ Naratriptan is effective in alleviating migraine headache and associated symptoms such as photophobia, phonophobia and nausea. It is also effective in preventing the recurrence of headache symptoms.

▴ In general the efficacy of naratriptan is similar to that of sumatriptan in treating migraine; however, naratriptan is associated with a lower incidence of headache recurrence than sumatriptan.

▴ Studies have shown that the tolerability of naratriptan is good, with the overall incidence of adverse events during treatment with naratriptan at doses up to 2.5mg similar to that observed with placebo.

▴ Naratriptan had no clinically significant effect on blood pressure or heart rate.

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  1. 1.Adis International LtdMairangi Bay, Auckland 10New Zealand

Personalised recommendations